<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05114239</url>
  </required_header>
  <id_info>
    <org_study_id>1227</org_study_id>
    <nct_id>NCT05114239</nct_id>
  </id_info>
  <brief_title>Topical Timolol: a Comparison of Surgical Outcomes</brief_title>
  <official_title>Topical Timolol: a Comparison of Surgical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keith G. LeBlanc, Jr, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Louisiana State University Health Sciences Center in New Orleans</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is&#xD;
      currently emerging in the literature. The investigators will enroll 30 participants in a&#xD;
      split scar study who have their skin cancer surgically removed resulting in a linear wound&#xD;
      equal to or longer than 4cm. The objective of this randomized study is to determine the&#xD;
      safety and efficacy of 0.25% timolol in promoting wound healing in wound closed primarily&#xD;
      greater than or equal to 1.5 cm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Topical timolol has shown in case series to improve healing time and cosmetic outcome of&#xD;
      ulcerated or non-healing wounds with improved cosmetic outcome when compared to standard&#xD;
      wound care. There is currently no research detailing if this improved outcome is applicable&#xD;
      when used with wounds approximated with sutures.&#xD;
&#xD;
      Mechanism of action is not fully elucidated but improved keratinocyte migration and&#xD;
      suppression of the inflammatory cascade is thought to improve wound healing. Skin cancer&#xD;
      surgeries have morbidity for patients as they are often in cosmetically sensitive locations.&#xD;
      Improving cosmetic outcomes of surgical scars could improve patient outcomes and overall&#xD;
      satisfaction.&#xD;
&#xD;
      The goal of this study is to determine if topical timolol will improve long-term cosmetic&#xD;
      outcomes of surgical scars and thereby improve patient outcomes. There is great variability&#xD;
      in how a surgical site heals depending on patient factors as well as surgical site location.&#xD;
      The investigators will perform a split scar study to allow each patient to be their own&#xD;
      control to account for this variability.&#xD;
&#xD;
      To assess the efficacy and safety of topically applied 0.25% timolol in promoting wound&#xD;
      healing in surgical primary linear wound greater than or equal to 4cm versus standard of care&#xD;
      (SOC) by:&#xD;
&#xD;
        1. Evaluating cosmetic outcomes of surgical wounds in terms of blinded physician and&#xD;
           patient assessment at 30 days and 90days following suture removal&#xD;
&#xD;
        2. Evaluating patient discomfort by patient questionnaire.&#xD;
&#xD;
        3. Determining the side effects associated to 0.25% topical timolol versus SOC;&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observed cosmetic difference of scar in treatment side versus control: Yes or no</measure>
    <time_frame>1 month after suture removal</time_frame>
    <description>Photo review of objective cosmetic difference by blinded physician</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed cosmetic difference of scar in treatment side versus control: Yes or no</measure>
    <time_frame>3 months after suture removal</time_frame>
    <description>Photo review of objective cosmetic difference by blinded physician</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Wound Heal</condition>
  <arm_group>
    <arm_group_label>Timolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Timolol 0.25% applied to distal or posterior half of wound edge twice daily prior and adjunct to prior wound care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Wound Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Petrolatum ointment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol 0.25% Ophthalmic Solution</intervention_name>
    <description>Applied to treatment side prior to standard wound care</description>
    <arm_group_label>Timolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Wound Care</intervention_name>
    <description>Wound is washed twice a day with soap and then petrolatum and a bandage is applied.</description>
    <arm_group_label>Standard Wound Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  skin wounds greater than or equal to 4cm, closed primarily and linearly following&#xD;
             standard excision or Mohs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past medical history of psoriasis&#xD;
&#xD;
          -  known history of sensitivity to beta blockers or topical timolol&#xD;
&#xD;
          -  pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith G LeBlanc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LSU HSC New Orleans</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Taylor G Dickerson, MD</last_name>
    <phone>(504) 568-7110</phone>
    <email>tgrif3@lsuhsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keith LeBlanc, MD</last_name>
    <phone>(504) 644-4226</phone>
    <email>klebl2@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Skin Surgery Centre</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taylor G Dickerson, MD</last_name>
      <phone>225-955-3679</phone>
      <email>tgrif3@lsuhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Keith Leblanc, MD</last_name>
      <phone>504-644-4226</phone>
      <email>kleb12@lsuhsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Keith Leblanc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Louisiana State University Health Sciences Center in New Orleans</investigator_affiliation>
    <investigator_full_name>Keith G. LeBlanc, Jr, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Timolol</keyword>
  <keyword>Wound healing</keyword>
  <keyword>Surgical Wounds</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

